long term side effects of glp-1 receptor agonists The expanding role agonists: a narrative review of current evidence and future directions Long-term Success of GLP-1s Hinges

In a 35-year-old, this is manageable

It may also slow digestion and suppress appetite

Byetta (exenatide) was the first glucagon-like peptide-1 agonist medication introduced in 2005

This might mean fewer patients needing expensive treatments like dialysis or hospitalizations, potentially easing overall healthcare utilization down the line

The glucose-dependent effects theory highlights that both hormones work in glucose-dependent ways but with different patterns

Pemvidutide and survodutide are both GLP-1/glucagon dual agonists being developed for obesity and MASH, but survodutide is further ahead in clinical development with more advanced Phase 3 programs, higher-tier regulatory designations (Breakthrough Therapy vs Fast Track), and greater weight loss in Phase 2 (18.7% vs 15.6%)